ZHBIO(SZ:300653)2022-12-03 10:20Financial Performance - In 2018, the company achieved product sales revenue of CNY 216 million, a year-on-year increase of 17.92% [2] - The total sales volume reached 268,800 units, reflecting a growth of 45.67% compared to the previous year [2] - The net profit attributable to shareholders was approximately CNY 85.82 million, marking a 39.15% increase year-on-year [2] Product Sales Overview - Sales revenue from oral repair membranes grew by 21.22% year-on-year, with sales volume increasing by 51.10% [2] - Sales revenue from bone repair materials exceeded CNY 11.19 million, accounting for over 5% of total revenue [3] Inventory and Market Strategy - The increase in inventory levels in 2018 and Q1 2019 was due to enhanced market development efforts and rising market demand [2] - The company aims to ensure market supply by increasing inventory quantities [2] R&D and Product Development - Active biological bone has been accepted by the National Medical Products Administration in November 2018 and is currently under priority review [2] - Ongoing R&D projects include materials for endometrial repair and various other medical applications [2][3] Sales Channels and Profit Margins - In 2018, distribution accounted for approximately 70% of sales with a gross margin of 91.8%, while direct sales made up nearly 30% with a gross margin of 96.1% [3] Future Plans and Strategic Vision - The company aims to be a leader in the field of regenerative medicine, focusing on the industrialization of biological regenerative materials [3] - Plans for 2019 include enhancing management precision, strengthening marketing teams, and accelerating new product development [4]